PrintThe Burrill Report
The Burrill Report (October 4, 2010): Seeing an Opportunity in Biosimilars (.MP3,13.66 Mb)
As the FDA readies for hearings in November on the pathway for biosimilars, companies are already eyeing new market opportunities. One company positioning itself to capitalize on the introduction of biosimilars in the United States is Antares Pharma. Antares believes its technology for patient self injection will be a critical market differentiator for companies looking to introduce biosimilars. We spoke to Paul Wotten, president and CEO of Antares, about how the market for biosimilars will likely differ from that of small molecule generics, what the company’s experience has been in Europe with its partner Teva, and why companies will not be able to rely on price alone as a way to differentiate themselves.
September 30, 2010
http://www.burrillreport.com/article-seeing_an_opportunity_in_biosimilars.html
BUSINESS STRATEGY
Seeing an Opportunity in Biosimilars
Podcast: October 4, 2010[Please login to post comments]
- Why Biotech Investor Finds Next-Gen Biofuels Attractive
In contrast to healthcare biotechs, real R&D; spending in energy is just beginning. Read More - Amyris completes IPO
Company prices below expectations but rises in aftermarket trading. Read More - Court Ruling Increases Pressure on Sanofi
Generic competition adds pressure to buy Genzyme. Read More - Embryonic Stem Cell Research Funding Gets a Reprieve
U.S. appeals court overturns lower court’s injunction on federally funded research. Read More - Finding Biomarkers for Drug-Induced Serious Adverse Events
Public-private partnership enters the second stage of effort to identify predictive genetic markers of rare adverse reactions to existing medications. Read More - Endo snaps up Qualitest for $1.2 billion
Acquisition builds out pain franchise and generics lineup. Read More - Cypress and Ramius Renew Battle
Biotech and hedge fund lock horns over control. Read More - Sanofi Forges Agreement with Covance Worth Up to $2.2 Billion
The French pharmaceutical giant continues to look beyond its own walls to fill the void from drugs going off-patent. Read More - Novartis to Pay $422.5 Million to Settle Criminal and Civil Allegations with U.S. Attorney’s Office
The weekly round-up of failed trials, missed targets and other business mishaps. Read More - Barcoding Life
International initiative aims to build a digital identification system of biodiversity. Read More
.gif)
.gif)
- Sanofi Goes Hostile With Genzyme Bid
The New York Times - Pioneer of In Vitro Fertilization Wins Nobel Prize
The New York Times - Children Exposed to Virus Weigh 52 Pounds More, Obesity Researchers Find
Bloomberg - Biotech salmon faces scrutiny at FDA panel
Reuters - New Drugs Stir Debate on Rules of Clinical Trials
The New York Times - FDA staff question Arena diet drug, shares plunge
Reuters - Top Genentech research exec departing for academia
Reuters - Health Plan Won’t Fuel Big Spending, Report Says
The New York Times - Lilly Invests $150 Million With Venture Firms Seeking New Drug Candidates
Bloomberg - Genzyme Investors Push for Sanofi Bid of $75 a Share
Bloomberg